A researcher at the Huntsman Cancer Institute evaluated a noninvasive skin imaging technology designed to accurately differentiate between common moles and melanoma. This technology has the potential to enhance melanoma screening while reducing the necessity for unnecessary biopsies, according to a press release dated February 24, 2026.
In other research developments, the drug daraxonrasib has shown promise for patients with NRAS-driven melanoma. This could offer new options for those with advanced disease who lack effective targeted treatments, according to a press release from July 16, 2026.
A novel oral combination drug therapy evaluated at the Huntsman Cancer Institute could help treat and prevent melanoma from spreading to the brain. Brain metastasis is identified as a primary cause of death from melanoma, according to a press release from March 20, 2025.
Research has also explored the relationship between tattoos and skin cancer. A study found that individuals with multiple tattoo sessions have a lower risk of melanoma, though experts stated that more research is required to confirm these findings and investigate the potential mechanisms involved, according to a press release from September 17, 2025.
Medical reviews have highlighted gaps in skin cancer care, noting that older adults and rural residents are more likely to receive late diagnoses for aggressive skin cancers. Experts stated that early detection and tailored strategies are necessary to improve outcomes, according to a news report from July 21, 2025.
